Methotrexate lung cancer

Antimetabolites Methotrexate Lung cancer, Colon cancer, Teratocardnoma, T cell lymphoma... 

Phenytoin Phenobarbital Vinblastine Carmustine Methotrexate Lung cancer with brain metastases Phenytoin ieveis feii from 9.4 to 5.6 micrograms/mL 24 hours after vinblastine. Patient fitted. Phenytoin ieveis returned to normai 2 weeks after chemotherapy. Phenobarbitai ieveis unaffected. 4... 

In phase II studies with topotecan alone, there is cytotoxic activity in lung cancer with intermittent dose schedules (33), as well as in lung cancer patients with topoisomerase II refractory disease (34). In advanced head and neck cancer topotecan is well-tolerated and has single-agent activity similar to that of cisplatin, 5-fluorouracil, and methotrexate... 

Cyclophosphamide is a component of CMF (cyclophosphamide, methotrexate, 5-fluorouracil) and other drug combinations used in the treatment of breast cancer. Cyclophosphamide in combination may produce complete remissions in some patients with ovarian cancer and oat cell (small cell) lung cancer. Other tumors in which benehcial results have been reported include non-oat cell lung cancers, various sarcomas, neuroblastoma, and carcinomas of the testes, cervix, and bladder. Cyclophosphamide also can be employed as an alternative to azathioprine in suppressing immunological rejection of transplant organs. 

Forty patients with lung cancer, treated with a combination of cisplatin, mitomycin, vinblastine, doxorubicin, cyclosphosphamide, and methotrexate, had a significant post-treatment increase in fibrinopeptide A and a fall in fibrinolytic activity, reflected by a fall in functional tissue activator this appeared to be cumulative, depending on the extent of drug exposure (184). 

The classic antifolate methotrexate MTX continues to be an important component of the chemotherapeutic armamentarium for a variety of cancers including pediatric ALL, osteogenic sarcoma, lymphoma, and breast cancer. Raltitrexed, another anti-folate, is used throughout much of the world outside of the United States for advanced colorectal cancer. Finally, Peme-trexed was approved in 2004 for the treatment of pleural mesothelioma and shortly thereafter as a second line treatment for nonsmall cell lung cancer. These drugs mimic the natural folate molecule and in so doing utilize the membrane-bound reduced folate carrier (RFC) protein system to gain entry into the cell. 

There is also a report that suggests that methotrexate inhibits the renal clearance of cisplatin. The renal clearance of platinum in 4 of 5 patients with non-small-cell lung cancer given cisplatin 50 mg/m and methotrexate 40 mg/m was reduced in the first 6 hours after administration (50% lower in the first 3 hours). Apart from a transient increase in serum urea nitrogen and creatinine in one patient, there was no sign of nephrotoxicity with concurrent use. ... 

Ms. Thompson has cancer of the lung and will begin a treatment regimen with methotrexate. Discuss important preadministration assessments you would perform before beginning therapy with methotrexate. 

Methotrexate Generic (when used for cancer] Acute lymphocytic leukemia meningeal leukemia carcinoma of head and neck region, lung non-Flodgkin lymphomas Blood disorders (anemia, leukopenia, thrombocytopenia] Gl distress (including ulceration of Gl tract] skin disorders (rashes, photosensitivity, hair loss] hepatotoxicity CNS effects (headaches, drowsiness, fatigue]... 

---